🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 20 of 857 · Phase 3 first, then by program name

  1. Apremilast, Apremilast, Apremilast, Apremilast placebo product is supplied to the clinic as 10, 20 and 30 mg tablets and 5 mg/mL oral solution. The placebo product is the same as the drug product formulation except there is no active apremilast., Apremilast

    Amgen

    Juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  2. Aramchol free acid

    Galmed Pharmaceuticals

    Nonalcoholic Steatohepatitis (NASH)

    phase 3 small molecule on hold

    1 trial

  3. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  4. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted), Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  5. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  6. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  7. Aripiprazole

    Otsuka Beijing Research Institute

    Bipolar I

    phase 3 small molecule completed

    1 trial

  8. Aripiprazole IM Depot

    Otsuka Beijing Research Institute

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  9. Arm A Mylotarg plus DA Versus CPX-351

    Cardiff Oncology

    Acute Myeloid Leukaemia

    phase 3 small molecule active

    1 trial

  10. Armodafinil

    Teva Pharma GmbH

    Depression

    phase 3 small molecule completed

    4 trials

  11. Armodafinil

    Teva Pharma GmbH

    Excessive Daytime Sleepiness

    phase 3 small molecule completed

    1 trial

  12. Armodafinil

    Teva Pharma GmbH

    Traumatic Brain Injury

    phase 3 small molecule terminated

    2 trials

  13. Armodafinil

    Teva Pharma GmbH

    Narcolepsy

    phase 3 small molecule completed

    2 trials

  14. Armodafinil 100 to 250 mg/day

    Teva Pharma GmbH

    Excessive Daytime Sleepiness

    phase 3 small molecule completed

    1 trial

  15. Armodafinil 150 mg/day

    Teva Pharma GmbH

    Excessive Sleepiness

    phase 3 small molecule completed

    1 trial

  16. Armodafinil 150 mg/day

    Teva Pharma GmbH

    Obstructive Sleep Apnea

    phase 3 small molecule completed

    1 trial

  17. Armodafinil 250 mg/day

    Teva Pharma GmbH

    Obstructive Sleep Apnea

    phase 3 small molecule completed

    1 trial

  18. Armstrong Albuterol Sulfate Inhalation Aerosol

    Amphastar France Pharmaceuticals

    Asthma

    phase 3 small molecule terminated

    1 trial

  19. Aromatase Inhibitors

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 small molecule active

    1 trial

  20. Arsenic trioxide

    Teva Pharma GmbH

    Acute Myeloid Leukemia

    phase 3 small molecule terminated

    1 trial

  21. Arsenic trioxide

    Teva Pharma GmbH

    Acute Promyelocytic Leukemia

    phase 3 small molecule completed

    1 trial

  22. Artemether-lumefantrine

    AVENUE THERAPEUTICS, INC.

    Plasmodium Falciparum Malaria

    phase 3 small molecule completed

    1 trial

  23. Asacol®

    Tillotts Pharma AG

    Active Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  24. Asciminib

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources